Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities.

Published

Journal Article

Digoxin and midazolam are routinely used as probe drugs to measure in vivo activity of P-glycoprotein (P-gp) and cytochrome P450 3A4/5 (CYP3A), respectively. We investigated whether digoxin and midazolam could be coadministered to simultaneously determine P-gp and CYP3A activity without a significant pharmacokinetic interaction. In a randomized crossover design, digoxin (0.5 mg oral) or midazolam (2.0 mg oral) was administered individually or in combination (digoxin 1 hour after midazolam) to 14 healthy volunteers. Blood and urine samples were collected for up to 48 hours. Pharmacokinetic parameters of digoxin, midazolam and 1'-OH midazolam were evaluated to determine the presence of an interaction. The geometric mean ratios of all measured pharmacokinetic parameters of digoxin and midazolam were not significantly affected by coadministration. Coadministration of digoxin and midazolam can be used to simultaneously phenotype P-gp and CYP3A activity without a significant pharmacokinetic interaction.

Full Text

Duke Authors

Cited Authors

  • Kirby, B; Kharasch, ED; Thummel, KT; Narang, VS; Hoffer, CJ; Unadkat, JD

Published Date

  • November 2006

Published In

Volume / Issue

  • 46 / 11

Start / End Page

  • 1313 - 1319

PubMed ID

  • 17050796

Pubmed Central ID

  • 17050796

International Standard Serial Number (ISSN)

  • 0091-2700

Digital Object Identifier (DOI)

  • 10.1177/0091270006292625

Language

  • eng

Conference Location

  • England